Daratumumab biosimilar (Henlius)
达雷妥尤单抗生物类似药（复宏汉霖）
Report date: 2026/05/23 20:00:57
Base Information
Drug NameDaratumumab biosimilar (Henlius)
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory +[5]
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesShanghai Henlius Biologics Co Ltd
China Registration ClassN/A
Develop Information
Active CompaniesShanghai Henlius Biologics Co LtdShanghai Henlius Biotech IncShanghai Henlius Biopharmaceuticals Co Ltd
Inactive CompaniesN/A
Active Indications
Inactive IndicationsN/A
Other Information
ATC Code
Related LinksN/A